Why phase II trials in cervical chemoprevention are negative: What have we learned?

Cancer Causes and Control

Volumn 13, Issue 9, 2002, Pages 855-873

  Follen, Michele ^a   Vlastos, Anne Thérèse ^a   Meyskens Jr , Frank L ^b   Atkinson, E Neely ^a   Schottenfeld, David ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cervical cancer; Cervix; Chemoprevention; Randomized clinical trials; Surrogate endpoint biomarkers

Indexed keywords

3 INDOLEMETHANOL; ASCORBIC ACID; BETA CAROTENE; EFLORNITHINE; FOLIC ACID; RETINOIC ACID; RETINOL ACETATE; VIRUS PROTEIN;

ARTICLE; CALCULATION; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL EXAMINATION; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; OUTCOMES RESEARCH; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; SIDE EFFECT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHEMOPREVENTION; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIALS; UTERINE CERVICAL NEOPLASMS;

EID: 0036844104     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020660527600     Document Type: Article

References (79)

1. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-841.
2. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H (1993) Trends in cancer incidence and mortality. IARC Sci Publ: 121: 1-806.
3. American Cancer Society (2002) Cancer Facts & Figures 2002. Atlanta: American Cancer Society.
4. American Cancer Society (1995) Cancer Facts & Figures 1995. Atlanta: American Cancer Society.
5. Paavonen J, Koutsky LA, Kiviat N (1990) Cervical neoplasia and other STD-related genital-anal neoplasias. In: Holmes KK, Mardh PA, Sparling PF, Wiesner PJ, eds. Sexually Transmitted Diseases, 2nd Edn. New York: McGraw-Hill, pp. 561-592.
6. US Department of Health and Human Services, Centers for Disease Control and Prevention (1999) The National Breast and Cervical Cancer Early Detection Program At-a-Glance 1999. Atlanta: Centers for Disease Control and Prevention.
7. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH (1994) Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 271: 1866-1869.
8. Ollayos CW, Swogger KA (1995) Abnormal cervical smears in the military recruit population. Mil Med 160: 577-578.
9. Center for Disease Control (1994) Results from the national breast and cervical cancer early detection program, October 31, 1991-September 30, 1993. Morb Mortal Wkly Rep 43: 530-534.
10. Romney SL, Dwyer A, Slagle S, et al. (1985) Chemoprevention of cervix cancer: Phase I-II. A feasibility study involving the topical vaginal administration of retinyl acetate gel. Gynecol Oncol 20: 109-119.
11. Surwit EA, Graham V, Droegemueller W, et al. (1982) Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. Am J Obstet Gynecol 143: 821-823.
12. Meyskens FL Jr, Graham V, Chvapil M, et al. (1983) A phase I trial of β-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. J Natl Cancer Inst 71: 921-925.
13. Weiner SA, Surwit EA, Graham VE, et al. (1986) A phase I trial of topically applied trans-retinoic acid in cervical dysplasia - Clinical efficacy. Invest New Drugs 4: 241-244.
14. Graham V, Surwit ES, Weiner S, Meyskens FL (1986) Phase II trial of β-ALL-trans-retinoic acid for cervical intraepithelial neoplasia via collagen sponge and cervical cap. West J Med 145: 192-195.
15. Meyskens FL Jr, Surwit E, Moon TE, et al. (1994) Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J Natl Cancer Inst 86: 539-543.
16. Current Clinical Trials Oncology (2000) National Cancer Institute PDQ, Vol. 7, No. 1 (January-February) (protocol 13869).
17. Follen M, Atkinson EA, Schottenfeld D, et al. (2001) A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 7: 3356-3365.
18. Romney SL, Basu J, Vermund S, Palan P, Duttagupta C (1987) Plasma reduced and total ascorbic acid in human uterine cervix dysplasias and cancer. Ann NY Acad Sci 498: 132-143.
19. Current Clinical Trials Oncology (1994) National Cancer Institute PDQ, Vol. 1, No. 2 (March-April) (protocol 09315).
20. Romney SL, Ho GYF, Palan PR, et al. (1997) Effects of β-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 65: 483-492.
21. Manetta A, Schubbert T, Chapman J, et al. (1996) β-Carotene treatment of cervical intraepithelial neoplasia: A phase II study. Cancer Epidemiol Biomarkers Prev 5: 929-932.
22. Current Clinical Trials Oncology (1994) National Cancer Institute PDQ, Vol. 1, No. 2 (March-April) (protocol 09088).
23. Keefe KA, Schell MJ, Brewer C, et al. (1998) A randomized, double blind, phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 10: 1029-1035.
24. De Vet HCW, Knipschild PG, Willebrand D, Schouten HJA, Sturmans F (1991) The effect of beta-carotene on the regression and progression of cervical dysplasia: A clinical experiment. J Clin Epidemiol 44: 273-283.
25. Fairley CK, Tabrizi SN, Chen S, et al. (1996) A randomized clinical trial of beta carotene vs. placebo for the treatment of cervical HPV infection. Int J Gynecol Cancer 6: 225-230.
26. Mackerras D, Irwig L, Simpson JM, et al. (1999) Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer 79: 1448-1453.
27. Butterworth CE, Hatch KD, Soong SJ, et al. (1992) Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial. Am J Obstet Gynecol 166: 803-809.
28. Butterworth CE Jr, Hatch KD, Macaluso M, et al. (1992) Folate deficiency and cervical dysplasia. JAMA 267: 528-533.
29. Childers JM, Chu J, Voigt LF, et al. (1995) Chemoprevention of cervical cancer with folic acid: A phase II Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev 4: 155-159.
30. Mitchell MF, Tortolero-Luna G, Lee JJ, et al. (1998) Phase I dose de-escalation trial of α-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res 4: 303-310.
31. Bell MC, Crowley-Nowick P, Bradlow HL, et al. (2000) Placebo controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 78: 123-129.
32. Kjaer SK (1998) Risk factors for cervical neoplasia in Denmark. APMIS (Suppl.) 80: 1-41.
33. Muñoz N, Bosch FX (1997) Cervical cancer and human papillomavirus: Epidemiological evidence and perspectives for prevention. Salud Pública de México 39: 274-282.
34. Muñoz N, Bosch FX (1992) HPV and cervical neoplasia: Review of case-control and cohort studies. IARC Sci Publ 119: 251-261.
35. Bosch FX, Muñoz N, de Sanjosé S, et al. (1993) Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: A case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 2: 415-422.
36. Bosch FX, Manos MM, Muñoz N, et al. (1995) Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802.
37. zur Hausen H (1999) Yohei Ito Memorial Lecture: Papillomaviruses in human cancers. Leukemia 13: 1-5.
38. Lowy DR, Schiller JT (1998) Papillomaviruses: Prophylactic vaccine prospects. Biochim Biophys Acta 1423: M1-8.
39. Ostor G (1993) Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 12: 186-192.
40. Mitchell MF, Hittelman WN, Hong WK, et al. (1994) The natural history of cervical intraepithelial neoplasia: An argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev 3: 619-626.
41. Mitchell MF, Tortolero-Luna G, Cook E, et al. (1998) A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for the treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 92: 737-744.
42. Boone CW, Kelloff GJ, Steele VE (1992) Natural history of intraepithelial neoplasia in humans with implications for cancer chemopreventive strategy. Cancer Res 52: 1651-1659.
43. Mitchell MF, Hittelman WK, Lotan R, et al. (1995) Chemoprevention trials in the cervix: Design, feasibility, and recruitment. J Cell Biochem (Suppl.) 23: 104-112.
44. Goodman GE. The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II, and III objectives. Cancer Res 52 (9 Suppl.): 2752S-2757S.
45. Begg C, Cho M, Eastwood S, et al. (1996) Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276: 637-639.
46. Fahey MT, Irwig L, Macaskill P (1995) Meta-analysis of Pap test accuracy. Am J Epidemiol 141: 680-689.
47. Mitchell MF, Cantor SB, Ramanujam N, et al. (1999) Fluorescence spectroscopy for diagnosis of squamous intraepithelial lesions of the cervix. Obstet Gynecol 93: 462-470.
48. Mitchell MF, Cantor SB, Brookner C, et al. (1999) Screening for squamous intraepithelial lesions with fluorescence spectroscopy. Obstet Gynecol 94: 889-896.
49. Evans TRJ, Kaye SB (1999). Retinoids: Present role and future potential. Br J Cancer 80: 1-8.
50. Lippman SM, Davies PJA (1997) Retinoids, neoplasia and differentiation therapy. Cancer Chemother Biol Response Mod 17: 349-362.
51. Delia D, Aiello A, Lombardi L, et al. (1993) N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53: 6036-6041.
52. Bartsch D, Boye B, Baust C, zur Hausen H, Schwarz E (1992) Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J 11: 2283-2291.
53. Batova A, Danielpour D, Pirisi L, Creek KE (1992) Retinoic acid induces secretion of latent transforming growth factor β1 and β2 in normal and human papillomavirus type 16 - Immortalized human keratinocytes. Cell Growth Differ 3: 763-772.
54. Woodworth CD, Notario V, DiPaolo JA (1990) Transforming growth factors α1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J Virol 64: 4767-4775.
55. Pietrantoni M, Taylor DD, Gercel-Taylor C, et al. (1995) The regulation of HPV oncogene expression by folic acid in cultured human cervical cells. J Soc Gynecol Invest 2: 228.
56. Ruffin MT, Bailey JM, Underwood D, et al. (1999) The potential use of HPV copy number and E6/E7 expression as biomarkers in cervical dysplasia. Proc Am Assoc Cancer Res 40 (abstract 2850).
57. Ho GY, Burk RD, Klein S, et al. (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87: 1365-1371.
58. Comerci JT, Runowicz CD, Fields AL, et al. (1997) Induction of transforming growth factor α-1 in cervical intraepithelial neoplasia in vivo after treatment with β-carotene. Clin Cancer Res 3: 157-160.
59. Brewer CA, Wilczynski SP, Kurosaki T, Daood R, Berman ML (1997) Colposcopic regression patterns in high-grade cervical intraepithelial neoplasia. Obstet Gynecol 90: 617-621.
60. Butterworth CE Jr, Hatch KD, Macaluso M, et al. (1992) Folate deficiency and cervical dysplasia. JAMA 267: 528-533.
61. Auvinen M, Paasinen A, Andersson LC, Hölttä E (1992) Ornithine decarboxylase activity is critical for cell transformation. Nature 360: 355-358.
62. Nishioka K, Melgarejo AB, Lyon RR, Mitchell MF (1995) Polyamines as biomarkers of cervical intraepithelial neoplasia. J Cell Biochem 23: 87-95.
63. Verma AK, Boutwell RK (1987) Inhibition of carcinogenesis by inhibitors of putrescine biosynthesis. In: McCann PP, Pegg AE, Sjoerdsma A, eds. Inhibition of Polyamine Metabolism, Biological Significance and Basis for New Therapies. Orlando: Academic Press, pp. 249-258.
64. Tempero MA, Nishioka K, Knott K, Zetterman RK (1989) Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer Res 49: 5793-5797.
65. Boiko IV, Mitchell MF, Pandey DK, et al. (1997) DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of α-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 6: 849-855.
66. Bacus JW, Boone CW, Bacus JV, et al. (1999) Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials. Cancer Epidemiol Biomarkers Prev 8: 1087-1094.
67. Hu W, Boiko IV, Mitchell MF, Hittelman WN, et al. (1995) Sequential dysregulation of proliferation during cervical carcinogenesis. Proc Am Assoc Cancer Res 36: (abstract 3500).
68. Hu W, Mitchell MF, Boiko IV, et al. (1997) Progressive dysregulation of proliferation during cervical carcinogenesis as measured by MPM-2 antibody staining. Cancer Epidemiol Biomarkers Prev 6: 711-718.
69. Boiko IV, Mitchell MF, Hu W, et al. (1998) Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an α-difluoromethylornithine chemoprevention trial. Clin Cancer Res 4: 1383-1391.
70. Mitchell MF, Tortolero-Luna G, Lee JJ, et al. (1997) Polyamine measurements in the uterine cervix. J Cell Biochem Suppl 28-29: 125-132.
71. Chang YC, Riby J, Chang GH (1999) Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)-3,3′-diindolylmethane, a major in vivo product of dietary indole-3-carbinol. Biochem Pharmacol 58: 825-834.
72. Cover CM, Hsieh S, Cram EJ, et al. (1999) Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 59: 1244-1251.
73. Katdare M, Osborne MP, Telang NT (1998) Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals. Oncol Rep 5: 311-315.
74. Cover CM, Hsieh SJ, Tran SH, et al. (1998) Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273: 3838-3847.
75. Wong GY, Bradlow L, Sepkovic D, et al. (1997) Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl 28-29: 111-116.
76. Jin L, Oi M, Chen DZ, et al. (1999) Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV 16) transgenic mice. Cancer Res 59: 3991-3997.
77. Follen M, Schottenfeld D (2001) Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials. Cancer 91: 1758-1776.
78. Stoler MH, Schiffman M (2001) Atypical squamous cells of undetermined significance - Low-grade squamous intraepithelial lesion triage study (ALTS) group. JAMA 285: 2855-2856.
79. Follen M, Meyskens FL Jr, Atkinson EN. Schottenfeld D (2001) Why most randomized phase II cervical cancer chemoprevention trials are uninformative: Lessons for the future. J Natl Cancer Inst 95: 1293-1296.